

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Genscript Biotech Corporation

金斯瑞生物科技股份有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1548)

SUPPLEMENTAL ANNOUNCEMENT

Reference is made to the announcement of the Company dated 28 June 2017 in relation to the Deemed Disposal of BSJ Nanjing, Subscription of New Shares of Legend Cayman, and Connected Transaction in relation to the Deemed Disposal of Legend Cayman (the “**June Announcement**”), the supplemental announcement of the Company dated 17 July 2017 (the “**July Announcement**”), the announcement of the Company dated 28 August 2017 in relation to the Additional Subscription of New Shares of Legend Cayman and Connected Transaction in relation to the Deemed Disposal of Legend Cayman (the “**August Announcement**”), and the supplemental announcement of the Company dated 9 October 2017 (the “**October Agreement**”, together with the June Announcement, the July Announcement and the August Announcement, the “**Announcements**”). Capitalized terms used in this announcement shall have the same meanings as those defined in the Announcements.

As disclosed in the June Announcement and August Announcement and as at the date of this Announcement, the Cayman Fund, namely AquaPoint L.P., is an exempted limited partnership established in the Cayman Islands which is held as to 1.060%, 32.980%, and 65.960% interest by GS Corp, Ms. Wang, and Mr. Fan, respectively.

Further to the above information in relation to the Cayman Fund as disclosed, the Board was informed by Ms. Wang that on 13 October 2017 (after trading hours), (A) Ms. Wang as the assignor, GS Corp as the Cayman Fund’s general partner and Mr. Hu Zhiyong, being Ms. Wang’s spouse, as the assignee and also the trustee of a trust set up by Ms. Wang for family wealth and succession planning purpose (the “**Wang Trust**”) (the “**Assignee**”) entered into a deed of assignment and assumption of limited partnership interest (the “**Transfer Deed**”), pursuant to which (i) Ms. Wang

agreed to assign to the Assignee all of her limited partnership interest in the Cayman Fund (the “**Interest**”)(the “**Assignment**”) and the monetary price for the Assignment is zero because as of the date of this announcement, Ms. Wang has not paid her responsible capital contribution to the Cayman Fund, and (ii) the Assignee agreed to accept, and GS Corp gave its consent to, the Assignment; and (B) the Wang Trust as subscriber, Ms. Wang as one of the Cayman Fund’s limited partners and GS Corp as the Cayman Fund’s general partner entered into certain documents (the “**Subscription Documents**”) in connection with the admission of the Wang Trust as a new limited partner under the Amended and Restated Exempted Limited Partnership Agreement dated 25 May 2017 between GS Corp, Ms. Wang and other parties named therein (the “**Limited Partnership Agreement**”).

Upon the completion of the transactions under the Subscription Documents and the Transfer Deed, Ms. Wang will be released from her obligation under the Subscription Documents and the Limited Partnership Agreement, and the Assignee and/or the Wang Trust will assume all of the obligations, commitments and liabilities of Ms. Wang under the Limited Partnership Agreement, including but without limitation to making of capital contribution to the Cayman Fund in accordance with the terms of the Limited Partnership Agreement. Accordingly, the Cayman Fund will be held as to 1.060%, 32.980%, and 65.960% interest by GS Corp, the Wang Trust, and Mr. Fan, respectively.

As at the date of this announcement, neither the Legend Share Allotment and Issuance nor the Additional Legend Share Allotment and Issuance has been completed, which may or may not be proceeded. Investors are advised to exercise caution when dealing in shares of the Company.

By Order of the Board
Genscript Biotech Corporation
Dr. Zhang Fangliang
Chairman and Chief Executive Officer

Hong Kong, 16 October 2017

As at the date of this announcement, our executive Directors are Dr. ZHANG Fangliang, Ms. WANG Ye, and Mr. MENG Jiange; our non- executive Directors are Dr. WANG Luquan, Mr. HUANG Zuie-Chin, and Mr. PAN Yuexin; and our independent non-executive Directors are Mr. GUO Hongxin, Mr. DAI Zumian, and Ms. ZHANG Min.

* *For identification purposes only*